These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 32256682)

  • 21. Influenza Activity in the US During the 2020-2021 Season.
    Uyeki TM; Wentworth DE; Jernigan DB
    JAMA; 2021 Jun; 325(22):2247-2248. PubMed ID: 34028492
    [No Abstract]   [Full Text] [Related]  

  • 22. Intrahost dynamics of antiviral resistance in influenza A virus reflect complex patterns of segment linkage, reassortment, and natural selection.
    Rogers MB; Song T; Sebra R; Greenbaum BD; Hamelin ME; Fitch A; Twaddle A; Cui L; Holmes EC; Boivin G; Ghedin E
    mBio; 2015 Apr; 6(2):. PubMed ID: 25852163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral resistance in influenza viruses: laboratory testing.
    Laplante J; St George K
    Clin Lab Med; 2014 Jun; 34(2):387-408. PubMed ID: 24856534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preventing and treating secondary bacterial infections with antiviral agents.
    McCullers JA
    Antivir Ther; 2011; 16(2):123-35. PubMed ID: 21447860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deletions in the neuraminidase stalk region of H2N2 and H9N2 avian influenza virus subtypes do not affect postinfluenza secondary bacterial pneumonia.
    Chockalingam AK; Hickman D; Pena L; Ye J; Ferrero A; Echenique JR; Chen H; Sutton T; Perez DR
    J Virol; 2012 Apr; 86(7):3564-73. PubMed ID: 22278240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlates of vaccine protection from influenza and its complications.
    McCullers JA; Huber VC
    Hum Vaccin Immunother; 2012 Jan; 8(1):34-44. PubMed ID: 22252001
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the Impact of Optimal Health Education Programs on the Control of Zoonotic Diseases.
    Mhlanga A
    Comput Math Methods Med; 2020; 2020():6584323. PubMed ID: 32733595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modelling and optimal control of pneumonia disease with cost-effective strategies.
    Tilahun GT; Makinde OD; Malonza D
    J Biol Dyn; 2017 Aug; 11(sup2):400-426. PubMed ID: 28613986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs.
    McCaw JM; Wood JG; McCaw CT; McVernon J
    PLoS One; 2008 Jun; 3(6):e2362. PubMed ID: 18523549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal control strategies for the transmission risk of COVID-19.
    Lemecha Obsu L; Feyissa Balcha S
    J Biol Dyn; 2020 Dec; 14(1):590-607. PubMed ID: 32696723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal Control of Shigellosis with Cost-Effective Strategies.
    Edward S; Shaban N; Mureithi E
    Comput Math Methods Med; 2020; 2020():9732687. PubMed ID: 32908585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling the effects of drug resistant influenza virus in a pandemic.
    Brockmann SO; Schwehm M; Duerr HP; Witschi M; Koch D; Vidondo B; Eichner M
    Virol J; 2008 Oct; 5():133. PubMed ID: 18973656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimality of a time-dependent treatment profile during an epidemic.
    Jaberi-Douraki M; Moghadas SM
    J Biol Dyn; 2013; 7(1):133-47. PubMed ID: 23859002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive effects of COVID-19 control measures on influenza prevention.
    Wu D; Lu J; Liu Y; Zhang Z; Luo L
    Int J Infect Dis; 2020 Jun; 95():345-346. PubMed ID: 32283283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postviral Complications: Bacterial Pneumonia.
    Prasso JE; Deng JC
    Clin Chest Med; 2017 Mar; 38(1):127-138. PubMed ID: 28159155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mathematical framework for estimating pathogen transmission fitness and inoculum size using data from a competitive mixtures animal model.
    McCaw JM; Arinaminpathy N; Hurt AC; McVernon J; McLean AR
    PLoS Comput Biol; 2011 Apr; 7(4):e1002026. PubMed ID: 21552544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiviral prophylaxis during pandemic influenza may increase drug resistance.
    Eichner M; Schwehm M; Duerr HP; Witschi M; Koch D; Brockmann SO; Vidondo B
    BMC Infect Dis; 2009 Jan; 9():4. PubMed ID: 19154598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bacterial pneumonia and pandemic influenza planning.
    Gupta RK; George R; Nguyen-Van-Tam JS
    Emerg Infect Dis; 2008 Aug; 14(8):1187-92. PubMed ID: 18680640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vitamin D supplementation could reduce the risk of type A influenza infection and subsequent pneumonia.
    Grant WB
    Pediatr Infect Dis J; 2010 Oct; 29(10):987. PubMed ID: 20859185
    [No Abstract]   [Full Text] [Related]  

  • 40. Surveillance for antiviral resistance among influenza viruses circulating in Algeria during five consecutive influenza seasons (2009-2014).
    Ait-Aissa A; Derrar F; Hannoun D; Gradi EA; Scaravelli D; Bouslama Z
    J Med Virol; 2018 May; 90(5):844-853. PubMed ID: 29315673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.